PAR not yet [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2011-10-27 15:25 (5350 d 16:52 ago) – Posting: # 7554
Views: 18,185

Hi tOT,

“Method C” as proposed in this publication is not acceptable, as type I error is not controlled on the 5% level and alternative methods securing type I error control are available.


❝ They go on to suggest method B because "The authors demonstrate by simulations that the power of this method is only slightly lower than for “Method C”, resulting in comparable mean total number of subjects."


❝ Any comments?


Difficult.
It's their call, really. To distinguish between the methods in practice I think one needs:
  1. To decide which T/R is realistic. 0.95 is a guess but do you have any idea really apart from dissolution?
  2. You proposed number of subjects in stage 1 (n1).
  3. Futility vs. power at the given T/R and n1 for the entire range of CVs.
All in all that's just not straightforward. Especially not if the true T/R differs from the expectation. That blows the entire approach. Wouldn't it be wonderful to use some kinda meffud that takes te observed T/R from stage 1 into account *cough*cough*?

Sounds to me like you should use method B if you wish to avoid discussion and if in vivo T/R really is 0.95.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
141 visitors (0 registered, 141 guests [including 15 identified bots]).
Forum time: 08:18 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5